TNFRSF1A and myeloid sarcoma: Kümpfel et al. reported that 24% of MS patients with two additional TRAPS-compatible symptoms (including arthralgia/arthritis, urticarial rash, and severe fatigue) carry the TRAPS-associated low-penetrance TNFRSF1A R92Q mutation (89).